Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer

References

• Consensus Statement: treatment of early-stage breast cancer. National Institutes of Health Consensus Development Panel. J. Natl Cancer Inst. Monogr.11, 1–5 (1992).
   Google Scholar
• Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Panel members.Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann. Oncol.16(10), 1569–1583 (2005).
   PubMed Web of Science ®Google Scholar
• Mauriac L, Keshaviah A, Debled M et al. Predictors of early recurrence in postmenopausal women with hormone receptor positive breast cancer in the BIG I-98 trial. Eur. J. Cancer Suppl.4(2), 111 (2006) (Abstract 219).
   Google Scholar
• McArthur HL, Olivotto I, Gelmon, KA et al. Risk of early relapse in postmenopausal women with early stage, estrogen receptor positive (ER+) breast cancer on tamoxifen. Breast Cancer Res. Treat.94(Suppl. 1), S124 (2005) (Abstract 3001).
   Web of Science ®Google Scholar
• Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet365, 1687–1717 (2005).
   PubMed Web of Science ®Google Scholar
• Buzdar A, Valero V, Theriault RL et al. Pathological complete response to chemotherapy is related to hormone receptor status. Breast Cancer Res. Treat.82(Suppl. 1), S69 (2003) (Abstract 302).
   Google Scholar
• Gianni L, Zambetti M, Clark K et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol.23(29), 7265–7277 (2005).
   PubMed Web of Science ®Google Scholar
• Mamounas EP. Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies. Semin. Oncol.25, 31–35 (1998).
   PubMed Web of Science ®Google Scholar
• Dixon JM, Anderson TJ, Miller WR. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur. J. Cancer38(17), 2214–2221 (2002).
   PubMed Web of Science ®Google Scholar
• Beresford MJ, Ravichandran D, Makris A. Neoadjuvant endocrine therapy in breast cancer. Cancer Treat. Rev.33(1), 48–57, (2007).
   Google Scholar
• Gazet JC, Ford HT, Coombes RC et al. Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur. J. Surg. Oncol.20(3), 207–214 (1994).
   PubMedGoogle Scholar
• Robertson JF, Ellis IO, Elston CW, Blamey RW. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur. J. Cancer28A(4–5), 908–910 (1992).
   Google Scholar
• Huober J, Krainick-Strobel U, Kurek R, Wallwiener D. Neoadjuvant endocrine therapy in primary breast cancer. Clin. Breast Cancer5, 341–347 (2004).
   PubMedGoogle Scholar
• Semiglazov VF, Semiglazov VV, Dashyan GA et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer (2007) (Epub ahead of print).
   Google Scholar
• Abrial C, Mouret-Reynier MA, Cure H et al. Neoadjuvant endocrine therapy in breast cancer. Breast15(1), 9–19 (2006).
   Google Scholar
• Murray J, Young O, Renshaw L et al. Letrozole and anastrozole: a pre-operative study of their effects on ER positive breast cancers in postmenopausal women. Presented at: 27th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8–11 December 2004 (Abstract 406).
   Google Scholar
• Smith IE, Dowsett M, Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol.23, 5108–5116 (2005).
   PubMed Web of Science ®Google Scholar
• Banerjee S, Smith IE, Folkerd L et al.; IMPACT trialists. Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial. Ann. Oncol.16(10), 1632–1638 (2005).
   PubMed Web of Science ®Google Scholar
• Cataliotti L, Buzdar AU, Noguchi S et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative “Arimidex” compared to tamoxifen (PROACT) trial. Cancer106(10), 2095–2103 (2006).
   PubMed Web of Science ®Google Scholar
• Smith I, Cataliotti L. Anastrozole versus tamoxifen as neoadjuvant therapy for oestrogen receptor-positive breast cancer in postmenopausal women: the IMPACT and PROACT trials. Eur. J. Cancer Suppl.2, 47 (2004).
   Google Scholar
• Eiermann W, Paepke S, Appfelstaedt J et al. Letrozole Neo-Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann. Oncol.12, 1527–1532 (2001).
   PubMed Web of Science ®Google Scholar
• Renshaw L, Murray J, Young O, Cameron D, Miller WR, Dixon JM. Is there an optimal duration of neoadjuvant letrozole therapy? Presented at: 27th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8–11 December 2004 (Abstract 405).
   Google Scholar
• Miller WR, Dixon JM. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control9(Suppl. 2), 9–15 (2002).
   PubMedGoogle Scholar
• Semiglazov V, Kletsel A, Semiglazov V et al. Exemestane (E) versus tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1–2, T3N0–1, T4N0M0). J. Clin. Oncol.23(Suppl. 16), 11S (2005) (Abstract 530).
   PubMed Web of Science ®Google Scholar
• Krainick U, Astner A, Jonat W et al. Phase II study to define safety and efficacy of exemestane as preoperative therapy for postmenopausal patients with primary breast cancer – final results of the German Neoadjuvant Aromasin Initiative (GENARI). Breast Cancer Res. Treat.82(Suppl. 1), S55 (2003) (Abstract 239).
   Google Scholar
• Tubiana-Hulin M, Spyratos F, Becette V et al. Phase II study of neo-adjuvant exemestane in postmenopausal patients with operable breast cancer. Breast Cancer Res. Treat.82(Suppl. 1), S106 (2003) (Abstract 443).
   Google Scholar
• No authors listed. ACS surgical trial accrual campaign: get involved, make a difference. Bull. Am. Coll. Surg.91(3), 51–52 (2006).
   Google Scholar
• Paepke S, Tulusan A, Kiesel L et al. A multicenter study of pre-operative treatment with letrozole for optimal duration of treatment in postmenopausal women with ER and/or PGR positive breast cancer. Proc. Am. Soc. Clin. Oncol.22, 80 (2003) (Abstract 321).
   Google Scholar
• Park D, Karesen R, Noren T, Sauer T. Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications. Virchows Arch.451(1), 11–18 (2007).
   PubMedGoogle Scholar
• Dowsett M, Smith IE, Ebbs SR et al. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin. Cancer Res.12(3), S1024–S1030 (2006).
   PubMed Web of Science ®Google Scholar
• Howell A, Cuzick J, Baum M et al. ATAC Trialists’ Group. Results of the ATAC trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet365, 60–62 (2005).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Smith IE, Ebbs SR et al; IMPACT Trialists Group. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J. Natl Cancer Inst.99, 167–170 (2007).
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Coop A, Singh B et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res.63, 6523–6531 (2003).
   PubMed Web of Science ®Google Scholar
• Murray E, Renshaw L, Macaskill EJ et al. Factors predicting survival after neoadjuvant therapy with aromatase inhibitors. Breast Cancer Res. Treat.100(Suppl. 1), S23 (2006) (Abstract 101).
   Google Scholar
• Miller WR, White S, Dixon JM, Murray J, Renshaw L, Anderson TJ. Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br. J. Cancer94(7), 1051–1056 (2006).
   PubMedGoogle Scholar
• Larionov A, Murray E, Evans DB, Miller WR, Dixon JM. Changes in cyclins and CDKs mRNA expression during neoadjuvant treatment with letrozole. Breast Cancer Res. Treat.106(Suppl. 1), S280 (2007) (Abstract 6099).
   Google Scholar
• Akashi-Tanaka S, Omatsu M, Shimizu C et al. Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy. Breast16(5), 482–488 (2007).
   Google Scholar
• Miller WR, Ellis MJ, Tao Y, Bhatnagar A, Evans DB, Sasano H. Absence of post treatment tumour expression of aromatase is associated with reduced antiproliferative effects of letrozole (but not tamoxifen) in the P024 adjuvant endocrine therapy trial. Breast Cancer Res. Treat.100(Suppl. 1), S186 (2006) Abstract 4045).
   Google Scholar
• Miller WR, Renshaw L, Larionov A et al. Prediction of hormone response in breast cancer by microarray analysis of sequential tumour biopsies from patients receiving neoadjuvant therapy with letrozole. J. Clin. Oncol.23(Suppl. 16), 198S (2005) (Abstract 3025).
   Google Scholar
• Larionov A, Miller W, White S et al. High density micro-arrays do not accurately reflect the decrease in MKI67 in breast cancers during treatment with the aromatase inhibitors anastrozole and letrozole. Breast Cancer Res. Treat.100(Suppl. 1), S221–S222 (2006) (Abstract 5026).
   Google Scholar
• Dixon JM, Jackson J, Hills M et al. Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status. Eur. J. Cancer40(18), 2742–2747 (2004).
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol.19, 3808–3816 (2001).
   PubMed Web of Science ®Google Scholar
• Miller WR, Dixon JM, Macfarlane L, Cameron D, Anderson TJ. Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur. J. Cancer39(4), 462–468 (2003).
   PubMedGoogle Scholar
• Young O, Murray J, Renshaw L et al. Neoadjuvant letrozole is equally effective in Her 2 positive and negative breast cancers. Presented at: 27th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8–11 December 2004 (Abstract 411).
   Google Scholar
• Ellis MJ, Tao Y, Young O et al. Estrogen-independent proliferation is present in estrogen-dependent HER2-positive primary breast cancer after neoadjuvant letrozole. J. Clin. Oncol.24, 3019–3025 (2006).
   PubMed Web of Science ®Google Scholar
• Smith IE, Dowsett M, Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol.23, 5108–5116 (2005).
   PubMed Web of Science ®Google Scholar
• Thomas JSJ, Julian HS, Green RV, Cameron DA, Dixon JM. Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring. Histopathology51, 219–226 (2007).
   PubMed Web of Science ®Google Scholar
• Turner J, Bentey R, Tao Y et al. Changes in tumor grade with neoadjuvant endocrine therapy: morphological evidence for fundamental differences in the anti-tumor effects of letrozole and tamoxifen. Presented at: 27th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8–11 December 2004 (Abstract 407).
   Google Scholar
• Ellis MJ, Tao Y, Lin L et al. High nuclear p27kip1 levels predicts sensitivity to neoadjuvant letrozole in ER+ breast cancer independent of pAKT levels, PIK3CA mutation status and cell cycle effects: a potential role for p27kip1 in predicting enhanced autophagocytosis in response to aromatase inhibitor therapy. Breast Cancer Res. Treat.100(Suppl. 1), S187 (2006) (Abstract 4048).
   Google Scholar
• Ellis MJ, Tao Y, Bhatnagar AS et al. Cell-cycle complete response after neoadjuvant letrozole predicts superior relapse-free and overall survival: long-term follow- up of the letrozole P024 study. J. Clin. Oncol.25(Suppl. 18), S20 (2007) (Abstract 570).
   Google Scholar
• Llombart A, Galán A, Fuster C et al. Phase II trial with letrozole (2.5mg) to maximal response as neoadjuvant endocrine therapy in postmenopausal patients with ER/PgR[+] operable breast cancer. Eur. J. Cancer Suppl.4(2), 153 (2006) (Abstract 362).
   Google Scholar
• Dixon JM, Renshaw L, Young O et al. Anastrozole and letrozole, an investigation and comparison of quality of life, tolerability and morbidity. Breast Cancer Res. Treat.100(Suppl. 1), S24 (2006) (Abstract 105).
   Google Scholar
• Renshaw L, McHugh RGN, Williams L et al. Comparison of joint problems reported by patients in a randomized adjuvant trial of anastrozole and letrozole. Breast Cancer Res. Treat.106(Suppl.1), S108 (2007) (Abstract 2072).
   Google Scholar
• Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J. Clin. Oncol.18(22), 3758–3767 (2000).
   PubMed Web of Science ®Google Scholar
• Bonneterre J, Buzdar A, Nabholtz JM et al.; Arimidex Writing Committee; Investigators Committee Members. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer92(9), 2247–2258 (2001).
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovich M, Monnier A et al; on behalf of the Letrozole P025 Breast Cancer Study Group. Letrozole is superior to tamoxifen as first-line hormonal treatment of post-menopausal women with locally advanced or metastatic breast cancer (BC). Ann. Oncol.11(Suppl. 4), 155 (2000) (Abstract 489).
   Google Scholar
• Kaufmann M, Bajetta E, Dirix LY et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. The Exemestane Study Group. J. Clin. Oncol.18(7), 1399–1411 (2000).
   PubMed Web of Science ®Google Scholar
• Mauriac L, Keshaviah A, Debled M et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial. Ann. Oncol.18(5), 859–867 (2007).
   PubMed Web of Science ®Google Scholar
• Houghton J. Initial adjuvant therapy with anastrozole (A) reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (T) – data reported on behalf of the ATAC (‘Arimidex’, tamoxifen, alone or in Combination) Trialists’ group. Ann. Oncol.17(Suppl. 9), ix94 (2006) (Abstract 243PD).
   Google Scholar
• Baum M, Budzar AU, Cuzick J et al. ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet359(9324), 2131–2139 (2002). Erratum in: Lancet360(9344), 1520 (2002).
   PubMed Web of Science ®Google Scholar
• Thürlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med.353(26), 2747–2457 (2005). Erratum in: N. Engl. J. Med.354(20), 2200 (2006).
   PubMed Web of Science ®Google Scholar
• Coombes RC, Hall E, Gibson LJ et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med.350(11), 1081–1092 (2004). Erratum in: N. Engl. J. Med.351(23), 2461 (2004). N. Engl. J. Med.355(16), 1746 (2006). van de Velde C [added].
   PubMed Web of Science ®Google Scholar
• Coombes RC, Kilburn LS, Snowdon CF et al; Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet369(9561), 559–570 (2007). Erratum in: Lancet369(9565), 906 (2007).
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med.349(19), 1793–1802 (2003).
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl Cancer Inst.97(17), 1262–1271 (2005).
   PubMed Web of Science ®Google Scholar
• Dixon JM, Renshaw L, Young O et al. Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer. J. Clin. Oncol.24(Suppl. 18), S15 (2006) (Abstract 552).
   Web of Science ®Google Scholar
• Geisler J, Helle H, Ekse D et al. Letrozole (Femara) causes potent suppression of breast cancer tissue estrogen levels in the neoadjuvant setting. J. Clin. Oncol.24(Suppl. 18), S570 (2006) (Abstract 10532).
   Google Scholar
• Monnier A. Refining the postmenopausal breast cancer treatment paradigm: the FACE trial. Expert Rev. Anticancer Ther.6(10), 1355–1359 (2006).
   PubMed Web of Science ®Google Scholar
• Jonat W, Mundhenke C. The FACE Trial: letrozole or anastrozole as initial adjuvant therapy? Cancer Invest.25(1), 14–18 (2007).
   PubMed Web of Science ®Google Scholar